Role of endogenous angiogenesis inhibitors in down syndrome

Journal of Craniofacial Surgery

Volumn 20, Issue SUPPL. 1, 2009, Pages 595-596

  Ryeom, Sandra ^a   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Cancer; Down syndrome; Endogenous angiogenesis inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARCINOGENESIS; CONGENITAL BLOOD VESSEL MALFORMATION; DIABETIC RETINOPATHY; DISEASE COURSE; DOWN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADAM PROTEINS; ANGIOGENESIS INHIBITORS; CHROMOSOMES, HUMAN, PAIR 21; COLLAGEN TYPE XVIII; DOWN SYNDROME; ENDOSTATINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1; VASCULAR MALFORMATIONS;

EID: 68249114052     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e3181927f47     Document Type: Article

References (21)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936
3. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309
4. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442
5. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974
7. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
8. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511
9. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285
10. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787
11. Hassold TJ, Jacobs PA. Trisomy in man. Annu Rev Genet 1984;18:69-97
12. Ylä-Herttuala S, Luoma J, Nikkari T, et al. Down's syndrome and atherosclerosis. Atherosclerosis 1989;76:269-272
13. Fulcher T, Griffin M, Crowley S, et al. Diabetic retinopathy in Down's syndrome. Br J Ophthalmol 1998;82:407-409
14. Greene AK, Kim S, Rogers GF, et al. Risk of vascular anomalies with Down syndrome. Pediatrics 2008;121:e135-140
15. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1893 to 1997: a population-based study. Lancet 2002;359:1019-1025
16. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-814
17. Folkman J, Kalluri R. Tumor Angiogenesis. In: Kufe DW, Pollock RE, Weichselbaum RR, eds. Cancer Medicine 6th ed. Hamilton, Ontario: BC Decker, 2003:161-194
18. Lee NV, Sato M, Annis DS, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 2006;25:5270-5283
19. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003;278:23656-23665
20. Iizuka M, Abe M, Shiiba K, et al. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res 2004;41:334-344
21. Minami T, Horiuchi K, Miura M, et al. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem 2004;279:50537-50554